Speciality Medicines IPO
GMP, Subscription, Price, Dates & Financial Details
Pharmaceutical & Drugs
Incorporated in 2021, Speciality Medicines Limited operates in the marketing and distribution of specialty pharmaceutical formulations. The company focuses on high-value oral and injectable medicines used in the treatment of complex and chronic health conditions.Its product portfolio includes a…
Open Date
Fri, 20 Mar 2026
Close Date
Tue, 24 Mar 2026
Price Band
₹ 117 – 124
Lot Size
1000
Issue Size
₹ 29.00 Cr
Minimum Investment
₹ 248,000 (2000 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Speciality Medicines IPO has successfully completed its IPO process and is now listed on BSE SME Platform. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹29.00 Crore, comprising a fresh issue of 22.00 Lakh equity shares aggregating to ₹27.00 Crore.
The Speciality Medicines IPO remained open for subscription from March 20, 2026, to March 24, 2026. The basis of allotment was finalized on March 25, 2026, and the company's shares were listed on BSE SME Platform on March 30, 2026.
The company had fixed the price band at ₹117 to ₹124 per share, with a lot size of 1000 shares. Retail investors were required to make a minimum investment of ₹248,000 (based on the upper price band) to apply for one lot.
Skyline Financial Services Private Ltd served as the registrar to the issue. Unistone Capital Pvt Ltd acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Speciality Medicines Limited is now a publicly listed company on BSE SME Platform. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Speciality Medicines IPO Timeline (Tentative)
- IPO Open Date
- Fri, 20 Mar 26
- IPO Close Date
- Tue, 24 Mar 26
- Basis of Allotment
- Wed, 25 Mar 26
- Initiation of Refunds
- Fri, 27 Mar 26
- Credit of Shares to Demat
- Fri, 27 Mar 26
- Listing Date
- Mon, 30 Mar 26 — NSE & BSE
Open Date
20 March 2026
Close Date
24 March 2026
Basis Of Allotment
25 March 2026
Listing Date
30 March 2026
IPO Subscription
Check Live Subscription →The Speciality Medicines IPO has received bids for 73,31,000 shares against 32,89,000 shares offered, resulting in an overall subscription of 2.23x. the NII category is subscribed 2.01x, Retail Investors 0.85x, and QIBs 96.24x. Within the NII category, BNII is subscribed 2.7x, while SNII is subscribed 0.64x.
QIB
96.24x
NII
2.01x
BNII
2.7x
SNII
0.64x
RII
0.85x
Total
2.23x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 10,90,000 shares, representing 49.55% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 21,000 shares (0.95%), while Non-Institutional Investors (NIIs) receive 10,89,000 shares (49.5%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 21,000 | 0.95% |
| Non-Institutional | 1,089,000 | 49.5% |
| BNII | 726,000 | 33% |
| SNII | 363,000 | 16.5% |
| Retail Investors | 1,090,000 | 49.55% |
| Total | 2,200,000 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Revenue | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| Net Worth | 36.47 | 30.42 | 15.06 |
| Reserve & Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowings | 4.81 | 5.05 | 2.86 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Speciality Medicines Limited KPI Information
| Particular | Oct 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| ROE % | 18.11 | 37.85 | 27.95 | 42.69 |
| ROCE % | 16.68 | 33.39 | 36.9 | 50.22 |
| Debt / Equity | 0.13 | 0.17 | 0.19 | 0.61 |
| RoNW % | 16.61 | 28.3 | 19.47 | 28.6 |
| Pat Margin % | 16.49 | 14.77 | 10.66 | 7.32 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Speciality Medicines Ltd | 10 | 0.00 | 14.10 | 14.10 | 28.42 | 47.26 |
| Remus Pharmaceuticals Ltd | 10 | 10.41 | 65.21 | 65.21 | 15.02 | 434.25 |
| Trident Lifeline Ltd | 10 | 27.00 | 10.22 | 10.22 | 18.23 | 56.05 |
| Mono Pharmacare Ltd | 10 | 7.49 | 1.75 | 1.75 | 9.90 | 17.66 |
About Speciality Medicines Limited
Incorporated in 2021, Speciality Medicines Limited operates in the marketing and distribution of specialty pharmaceutical formulations. The company focuses on high-value oral and injectable medicines used in the treatment of complex and chronic health conditions.
Its product portfolio includes a diverse range of finished formulations available in multiple dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions.
The company follows a dual business model:
- Contract Manufacturing: Manufacturing finished pharmaceutical formulations for international markets.
- Marketing and Distribution: Sourcing, marketing, and distributing specialty pharmaceutical products across domestic and global markets.
Speciality Medicines Limited has established an expanding international presence, with product registrations (approved and under process) in countries including Jordan, Ethiopia, Uganda, Peru, and Namibia. The company has built a strong distribution network spanning over 20 states in India and more than 35 countries worldwide.
As of March 31, 2025, the company had 1 product registered overseas and 60 products under registration across five countries, contributing to its revenue pipeline.
As of August 31, 2025, the company employed 18 permanent staff across various functional departments.
Speciality Medicines IPO Promoters
- Parth B Goyani
- Goyani Sumit Babubhai
Promoters Holding
Holding Pre Issue
59.67%
Holding Post Issue
0.00%
Speciality Medicines IPO Objective
The Company Speciality Medicines IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Setting up of Research and Development (R&D) Center
- Product registration in the international markets
- Repayment/ prepayment, in full or part, of certain borrowings availed by our Company
- To Meet Working Capital Requirements
- General Corporate Purposes
Speciality Medicines Limited Address / Contact Details
Speciality Medicines Ltd.
913, One World West, S. No. 396, FP 119,
Village- Vejalpur, Ahmadabad City,
Ahmedabad, Gujarat, India,
Ahmedabad, Gujarat, 380051
Phone: +91 22 4604 5344
Email: investors.grievances@specialitymedicine.com
Website: http://www.specialitymedicine.com/
IPO Snapshot
Speciality Medicines IPO Lot Size
The Speciality Medicines IPO has a lot size of 1,000 shares. Retail investors require a minimum investment of ₹2,48,000 by applying for 2 lot (2,000 shares). The maximum application allowed for the retail category is 2 lots (2,000 shares), requiring an investment of ₹2,48,000.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | 248,000.00 |
| Retail (Max) | 2 | 2,000 | 248,000.00 |
| S-HNI (Min) | 3 | 3,000 | 372,000.00 |
| S-HNI (Max) | 8 | 8,000 | 992,000.00 |
| B-HNI (Min) | 9 | 9,000 | 1,116,000.00 |
Issue Reservation
- QIB — 0.95%
- NII — 49.5%
- RII — 49.55%
Book Running Lead Managers
- Unistone Capital Pvt Ltd
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Speciality Medicines IPO?
Speciality Medicines IPO is a Book-building IPO with a total issue size of ₹29 crore. The Speciality Medicines IPO price band is ₹117 to 124 per share. The Speciality Medicines IPO subscription opens on Fri, Mar 20, 2026, and closes on Tue, Mar 24, 2026. The Speciality Medicines IPO will be listed on the BSE. Skyline Financial Services Private Ltd is the registrar for the Speciality Medicines IPO.
When will the Speciality Medicines IPO open for subscription?
The Speciality Medicines IPO opens on Fri, Mar 20, 2026 and closes on Tue, Mar 24, 2026
What is Speciality Medicines IPO Price Band?
Speciality Medicines IPO Price Band is ₹117 to 124 per share.
What is Speciality Medicines IPO Lot Size?
Speciality Medicines IPO lot size is 1000 shares, Retail investors need a minimum investment of ₹248000 based on the upper price band
What is the minimum investment for Speciality Medicines IPO?
The minimum investment for Speciality Medicines IPO is ₹248000, based on one lot of 1000 shares at the upper price band of ₹124 per share.
How to apply for Speciality Medicines IPO?
Investors can apply for the Speciality Medicines IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Tue, Mar 24, 2026. The application amount remains blocked until the Speciality Medicines IPO allotment is finalized.
What is Speciality Medicines IPO Issue Size?
Speciality Medicines IPO issue size is ₹29 crores.
What is the Speciality Medicines IPO Allotment Date?
Speciality Medicines IPO allotment date is Wed, Mar 25, 2026.
Who is the Speciality Medicines IPO Registrar?
The registrar for Speciality Medicines IPO is Skyline Financial Services Private Ltd. Investors can go to Skyline Financial Services Private Ltd website to check Speciality Medicines IPO allotment status, refund processing, and other IPO-related information.
Who is the Speciality Medicines IPO Lead Manager?
The book-running lead managers (BRLMs) for the Speciality Medicines IPO are Unistone Capital Pvt Ltd. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Speciality Medicines IPO Red Herring Prospectus (RHP).